Table 2 |
F-MIC S</R> |
Enterobac- teriaceae, SSYC |
Pseudo- monas |
Acineto- bacter |
Staphylo- coccus |
Entero- coccus |
Strepto- coccus |
Pneumo- coccus |
H.influ- enzae |
M.ca- tarrhal |
C.ureal C.jeikei |
N.gonor- rhoeae |
N.menin- gitidis |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Method (see below) | A | A | A | A | A | B | B | B | B | B |
B
(nalidixic acid screen) |
B | |
| Amikacin | 8/16 | 8/16 | 8/16 | 8/16 | 8/16 | ent | strep | -- | IE | IE | -- | -- | -- |
| Gentamicin | 2/4 | 2/4 | 4/4 | 4/4 | 1/1 | ent | strep | -- | IE | IE | -- | -- | -- |
| Netilmicin | 2/4 | 2/4 | 4/4 | 4/4 | 1/1 | ent | strep | -- | IE | IE | -- | -- | -- |
| Tobramycin | 2/4 | 2/4 | 4/4 | 4/4 | 1/1 | ent | strep | -- | IE | IE | -- | -- | -- |
| Erythromycin | IE | -- | -- | -- | 1/2 | -- | 0.25/0.5 | 0.25/0.5 | 0.5/16 |
0.25/0.5 |
IE | -- | -- |
| Roxithromycin | IE | -- | -- | -- | 1/2 | -- | 0.5/1 | 0.5/1 | 1/16 | 0.5/1 | IE | -- | -- |
| Klarithromycin | IE | -- | -- | -- | 1/2 | -- | 0.25/0.5 | 0.25/0.5 | 1/32 | 0.25/0.5 | IE | -- | -- |
| IE | -- | -- | -- | 1/2 | -- | 0.25/0.5 | 0.25/0.5 | 0.12/4 |
0.5/0.5 |
IE | 0.25/0.5 | -- | |
| IE | -- | -- | -- | IE | -- | 0.25/0.5 | 0.25/0.5 | 0.12/8 | 0.25/0.5 | -- | -- | -- | |
| IE | -- | -- | -- | 0.25/0.5 | -- | 0.5/0.5 | 0.5/0.5 | -- | -- | IE | -- | -- | |
| Fusidic acid | 0.5/0.5 | -- | -- | -- | 0.5/0.5 | -- | IE | IE | -- | -- | 0.5/0.5 | -- | -- |
| Fusidic acid | IE | -- | -- | -- | 1/1 | -- | IE | -- | -- | -- | -- | -- | -- |
| Kloramfenikol | 8/8 | 8/8 | -- | -- | 8/8 | -- | -- | (8/8) | 2/2 | -- | IE | -- | 2/8 |
| Chloramphenicol | IE | 8/8 | -- | -- | 8/8 | -- | 8/8 | 8/8 | 1/2 | 1/2 | -- | -- | 2/4 |
| Doxycyklin* | (2/2)* | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Doxycyklin | IE | -- | -- | -- | 1/2 | -- | 1/2 | 1/2 | 1/2 | 1/2 | -- | IE | -- |
| Tetracyklin* | 2/2 | -- | -- | -- | 2/2 | IE | 2/2 | 2/2 | 2/2 | 2/2 | -- | 0.12/1 | -- |
| Tetracyklin* | IE | -- | -- | -- | 1/2 | -- | 1/2 | 1/2 | 1/2 | 1/2 | -- | (0.5/1)# |
1/2 (Prophylaxis) |
| Tigecyklin | 0.25/0.5 | 1/2** | -- | IE | 0.5/0.5 | 0.25/0.5 | 0.25/0.5 | IE | IE | IE | IE | IE | IE |
| F-MIC | Enterobac- teriaceae |
Pseudo- monas |
Acineto- bacter |
Staphylo- coccus |
Entero- coccus |
Strepto- coccus |
Pneumo- coccus |
H.influ- enzae |
M.ca- tarrhal |
C.ureal C.jeikei |
N.gonor- rhoeae |
N.menin- gitidis |
|
| Rifampicin | 1/1 | -- | -- | -- | 1/1 | -- | 1/1 | 1/1 | -- | -- | IE | -- | 1/1 (Prophylaxis) |
| Rifampicin | IE | -- | -- | -- | 0.06/0.5 | -- | 0.06/0.5 | 0.06/0.5 | 0.5/0.5 | IE | IE | -- | 0.25/0.25(Prophylaxis) |
| 4/8 | -- | -- | -- | 4/8 | 4/8 | 4/4 | 4/4 | -- | -- | IE | -- | -- | |
| 4/8 | -- | -- | -- | 4/8 | 4/8 | 4/4 | 4/4 | -- | -- | IE | -- | -- | |
| Linezolid | 2/4 | -- | -- | -- | 4/4 | 4/4 | 2/4 | 2/4 | -- | -- | IE | -- | -- |
| Daptomycin* | IE | -- | -- | -- | 1/1 | IE | 1/1 | IE | -- | -- | -- | -- | -- |
| IE | -- | -- | -- | 1/2 |
E.faecalis: R E.faecium: 1/4 |
-- | -- | -- | -- | -- | -- | -- | |
| Metronidazole | 4/4 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Metronidazole | IE | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Norfloxacin (U) | 0.5/1 | 0.5/1 | -- | -- | -- | -- | -- | -- | -- | -- | -- | IE | -- |
| Ciprofloxacin | 0.5/1 | 0.5/1 | 0.5/1 | 1/1 | 1/1**** | -- | -- | 0.12/2 | 0.5/0.5 | 0.5/0.5 | IE | 0.03/0.06 | 0.03/0.06 (Prophylaxis) |
| Ofloxacin | 0.5/1 | 0.5/1 | -- | -- | 1/1**** | -- | -- | 0.12/4 | 0.5/0.5 | 0.5/0.5 | -- | 0.12/0.25 | IE |
| Levofloxacin | 1/2 | 1/2 | 1/2 | 1/2 | 1/2**** | -- | 1/2 | 2/2 | 1/1 | 1/1 | IE | IE | IE |
| Moxifloxacin | 0.5/1 | 0.5/1 | -- | -- | 0.5/1 | -- | 0.5/1 | 0.5/0.5 | 0.5/0.5 | 0.5/0.5 | IE | IE | IE |
| Nitrofurantoin | 32/32 | 32/32 | -- | 32/32 | 32/32 |
E.faecalis:
32/32 E.faecium: R |
32/32 | -- | -- | -- | -- | -- | -- |
| Nitrofurantoin (U) | IE | 64/64 | -- | -- | 64/64 | 64/64 | 64/64 | -- | -- | -- | -- | -- | -- |
| Trimetoprim | 2/4 | 2/4 | -- | -- | 2/4 | 2/4 | 2/4 | -- | -- | -- | IE | -- | -- |
| Trimethoprim (U) | IE | 2/4 | -- | -- | 2/4 | 0.032/1 | -- | -- | -- | -- | -- | -- | -- |
| TrimSulfa | 16/32 | 16/32 | -- | 16/32 | 16/32 | -- | 16/32 | 16/32 | 16/32 | 16/32 | IE | -- | -- |
| TrimSulfa (ratio 1:19) | IE | 2/4 |
Pseudo-monas: -- S.maltophilia: 4/4 |
2/4 | 2/4 | 0.032/1 | 1/2 | 1/2 | 0.5/1 | 0.5/1 | IE | -- | -- |
| Colistin | 2/2 | 2/2 | 2/2 | 2/2 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Colistin | IE | 2/2 | 2/2 | 2/2 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Fosfomycin-trometamol(U) | IE |
32/32 (endast på licens) |
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Spectinomycin | 32/32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 32/32 | -- |
| Spectinomycin | IE | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 64/64 | -- |
*Daptomycin susceptibility testing -
MIC-determination on MH only.
(U) = Urinary tract infections only.
#Neisseria
gonorrhoeae – tetracycline is not recommended for treatment of gonorrhoea,
and resistance to tetracycline mainly constitutes an epidemiological marker.
| Listeria Medium B |
Penicillin G (2/2), Ampicillin (2/2), Meropenem (0.5/0.5), TrimSulfa (2/4). Vid allergi hos gravida Erythromycin (0.5/0.5) som har sämre klinisk effekt. See EUCAST MIC-distributions for Listeria monocytogenes. |
| P.multocida Medium B |
Penicillin V (0.5/0.5), Ampicillin (0.5/0.5), Cefotaxime (0.12/1), Ciprofloxacin (0.12/0.25), Tetracycline (2/4) och TrimSulfa (2/4). See EUCAST MIC-distributions for P.multocida. |
| H.pylori Medium B |
Ampicillin (0.5/1), Clarithromycin (0.25/0.25), Tetracycline (2/2), Metronidazole (4/4). See EUCAST MIC-distributions for H. pylori. |
| Legionella pneumophila | See MIC-distributions for relevant antimicrobials (EUCAST MIC-distributions for L. pneumophila) |
| Bacteroides, Clostridium Medium B + Anaerobe incubation |
Penicillin G for Clostridium (0.25/1), Piperacillin/tazobactam (16/16), Imipenem (1/1), Meropenem (1/1), Clindamycin for Bacteroides 4/4, Clindamycin for Clostridium 4/4, Chloramphenicole (8/8), Tetracycline (2/2; proposed change: IE), Doxycycline (1/2; proposed change: IE), Metronidazole (4/4) |
| Stenotrophomonas maltophilia | Trimsulfa 4/4 mg/L (MIC-tests should be performed on Mueller-Hinton agar). Breakpoints for other antimicrobials are not given by SRGA or EUCAST. Clinical correlation between MIC-values and clinical outcome is lacking and testing is uncertain. When testing, always use Mueller Hinton medium. |
*Använd
tetracyklin (lappar, Etest och substans för MIC-bestämning) i all
resistensbestämning av tetracykliner. |
*Always use tetracyline
(discs, Etest and susbstance for MIC-determination) in all susceptibility testing
of tetracyclines. **Tigecycline has decreased activity against Morganella, Proteus and Providencia; susceptibility testing should be avoided. ***For dalfopristine-quinupristine it is recommended that the MIC is determined when there is need for susceptibility testing. |
Kursiv text anger en länk till en fotnot. För den som skriver ut tabellen på papper är det viktigt att även alla fotnoter skrivs ut och följer med tabellen. |
Text = a link to a footnote. If you print the table on paper, remember to print the footnotes - they contain important information on methodology. |
| 4/8 -
sättet att beskriva MIC-gränser (exempelvis 4/8) skall tolkas S< 4 och R>8 mg/l (obs! ändrades 2003 från R> till R>). IE - Klinisk effekt utesluts ej men in vitro och/eller in vivo dokumentation saknas. -- RAF avråder från resistensbestämning. Ej relevant behandlingsalternativ:
Proph - endast för profylax |
4/8 - the way breakpoints are
described - interpretate S< 4 mg/l and
R>8 mg/l (changed in 2003 from R> to R>). IE - Clinical effect is not ruled out but EUCAST has not been able to find enough evidence to make a breakpoint decision. -- SRGA advices against susceptibility testing. Not a relevant alternative:
Proph - prophylaxis only |
|
Metod: A = grundmedium utan tillsatser. Inkubation i luft, 35 - 37o C. B = grundmedium + 5% skakhästblod + NAD. Inkubation 35 - 37o C i 5 % CO2. |
Method: A = medium without additives. Incubation in air, 35 - 37o C. B = medium + 5% defibrinated horse blood + NAD. Incubation at 35 - 37o C in 5 % CO2. |